This “Adult-Onset Still Disease - Pipeline Insight, 2021,” report provides comprehensive insights about 2+ companies and 2+ pipeline drugs in Adult-Onset Still Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Adult-Onset Still Disease Understanding
Adult-onset Still's disease (AOSD) is a rare inflammatory disorder that affects the entire body (systemic disease). The cause of the disorder is unknown (idiopathic). It has similar symptoms to systemic-onset juvenile idiopathic arthritis; fever, rash, and joint pain. The specific symptoms and frequency of episodes vary from one person to another and the progression of the disorder is difficult to predict. A diagnosis of AOSD is usually made based upon thorough clinical evaluation, a detailed patient history, identification of characteristic findings, and a variety of tests may be performed to aid in the diagnosis, including blood tests and x-ray studies that reveal changes in the bones or joints or enlargement of the spleen or liver. Non-steroidal anti-inflammatory drugs (NSAIDs) are often used to treat symptoms of inflammation. In 2020, the U.S. Food and Drug Administration (FDA) approved Ilaris (canakinumab) to treat patients with active still's disease, including adult onset still's disease.
"Adult-Onset Still Disease - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Adult-Onset Still Disease pipeline landscape is provided which includes the disease overview and Adult-Onset Still Disease treatment guidelines. The assessment part of the report embraces, in depth Adult-Onset Still Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Adult-Onset Still Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Adult-Onset Still Disease R&D. The therapies under development are focused on novel approaches to treat/improve Adult-Onset Still Disease.
This segment of the Adult-Onset Still Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Tadekinig alfa is a recombinant human interleukin-18 binding protein (IL-18BP) that neutralizes IL-18. The drug is in Phase II clinical studies for the treatment of Adult-Onset Still Disease.
CERC 007 (formerly AEVI 007 or MEDI 2338) is a high affinity, fully human anti interleukin-18 monoclonal antibody. The drug is in Phase I clinical studies for the treatment of Adult-Onset Still Disease and Multiple myeloma. In May 2021, Cerecor announced that it had dosed its first patient in a Phase Ib open-label dose-escalation clinical trial of CERC-007 in patients with adult onset Still's disease (AOSD). The Company anticipates initial data to be reported in the third quarter of 2021.
This segment of the report provides insights about the different Adult-Onset Still Disease drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 2+ key companies which are developing the therapies for Adult-Onset Still Disease. The companies which have their Adult-Onset Still Disease drug candidates in the most advanced stage, i.e. Phase II include, AB2 Bio.
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Adult-Onset Still Disease therapeutic drugs key players involved in developing key drugs.
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Adult-Onset Still Disease drugs.
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Adult-Onset Still Disease Understanding
Adult-Onset Still Disease: Overview
Adult-onset Still's disease (AOSD) is a rare inflammatory disorder that affects the entire body (systemic disease). The cause of the disorder is unknown (idiopathic). It has similar symptoms to systemic-onset juvenile idiopathic arthritis; fever, rash, and joint pain. The specific symptoms and frequency of episodes vary from one person to another and the progression of the disorder is difficult to predict. A diagnosis of AOSD is usually made based upon thorough clinical evaluation, a detailed patient history, identification of characteristic findings, and a variety of tests may be performed to aid in the diagnosis, including blood tests and x-ray studies that reveal changes in the bones or joints or enlargement of the spleen or liver. Non-steroidal anti-inflammatory drugs (NSAIDs) are often used to treat symptoms of inflammation. In 2020, the U.S. Food and Drug Administration (FDA) approved Ilaris (canakinumab) to treat patients with active still's disease, including adult onset still's disease.
"Adult-Onset Still Disease - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Adult-Onset Still Disease pipeline landscape is provided which includes the disease overview and Adult-Onset Still Disease treatment guidelines. The assessment part of the report embraces, in depth Adult-Onset Still Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Adult-Onset Still Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Adult-Onset Still Disease R&D. The therapies under development are focused on novel approaches to treat/improve Adult-Onset Still Disease.
Adult-Onset Still Disease Emerging Drugs Chapters
This segment of the Adult-Onset Still Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Adult-Onset Still Disease Emerging Drugs
Tadekinig alfa: AB2 Bio
Tadekinig alfa is a recombinant human interleukin-18 binding protein (IL-18BP) that neutralizes IL-18. The drug is in Phase II clinical studies for the treatment of Adult-Onset Still Disease.
CERC-007: Cerecor
CERC 007 (formerly AEVI 007 or MEDI 2338) is a high affinity, fully human anti interleukin-18 monoclonal antibody. The drug is in Phase I clinical studies for the treatment of Adult-Onset Still Disease and Multiple myeloma. In May 2021, Cerecor announced that it had dosed its first patient in a Phase Ib open-label dose-escalation clinical trial of CERC-007 in patients with adult onset Still's disease (AOSD). The Company anticipates initial data to be reported in the third quarter of 2021.
Adult-Onset Still Disease: Therapeutic Assessment
This segment of the report provides insights about the different Adult-Onset Still Disease drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Adult-Onset Still Disease
There are approx. 2+ key companies which are developing the therapies for Adult-Onset Still Disease. The companies which have their Adult-Onset Still Disease drug candidates in the most advanced stage, i.e. Phase II include, AB2 Bio.
Phases
This report covers around 2+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Adult-Onset Still Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- Intravitreal
- Subretinal
- Topical
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Adult-Onset Still Disease: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Adult-Onset Still Disease therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Adult-Onset Still Disease drugs.
Adult-Onset Still Disease Report Insights
- Adult-Onset Still Disease Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Adult-Onset Still Disease Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions Answered
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Adult-Onset Still Disease drugs?
- How many Adult-Onset Still Disease drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Adult-Onset Still Disease?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Adult-Onset Still Disease therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Adult-Onset Still Disease and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Cerecor
- AB2 Bio
Key Products
- CERC-007
- Tadekinig alfa
Table of Contents
IntroductionExecutive Summary
Adult-Onset Still Disease: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Adult-Onset Still Disease - Analytical Perspective
Late Stage Products (Phase III)
- Comparative Analysis
Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
Mid Stage Products (Phase II)
- Comparative Analysis
Tadekinig alfa: AB2 Bio
- Product Description
- Research and Development
- Product Development Activities
Early Stage Products (Phase I)
- Comparative Analysis
CERC-007: Cerecor
- Product Description
- Research and Development
- Product Development Activities
Preclinical/Discovery Stage Products
- Comparative Analysis
Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
Inactive Products
- Comparative Analysis
Adult-Onset Still Disease Key Companies
Adult-Onset Still Disease Key Products
Adult-Onset Still Disease- Unmet Needs
Adult-Onset Still Disease- Market Drivers and Barriers
Adult-Onset Still Disease- Future Perspectives and Conclusion
Adult-Onset Still Disease Analyst Views
AppendixList of Tables
Table 1 Total Products for Adult-Onset Still Disease
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive ProductsList of Figures
Figure 1 Total Products for Adult-Onset Still Disease
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Companies Mentioned
A selection of companies mentioned in this report includes:
- Cerecor
- AB2 Bio
